Letter to the Editor: statistics and clinical perception of patients' reported outcomes for palbociclib and abemaciclib: a sliding doors story

J Comp Eff Res. 2023 Jun;12(6):e220212. doi: 10.57264/cer-2022-0212. Epub 2023 Apr 28.

Vittorio Gebbia^{1

2}, Maria Rosaria Valerio³, Federica Martorana^{4

5}, Maria Vita Sanò⁴, Paolo Vigneri⁵

¹ Kore University of Enna, Enna, 94100, Italy.
² Medical Oncology Units, La Maddalena Clinic for Cancer, Palermo, 90100, Italy.
³ Medical Oncology Unit, Policlinico P. Giaccone, University of Palermo, Palermo, 90100, Italy.
⁴ Medical Oncology Unit, Istituto Clinico Humanitas, Catania, 95100Italy.
⁵ Department of Clinical & Experimental Medicine, University of Catania, Catania - Italy, & Center of Experimental Oncology & Hematology AOU, Policlinico 'G. Rodolico - San Marco', Catania, 95100, Italy.

No abstract available

Keywords: abemaciclib; breast cancer; indirect comparison; palbociclib.

Publication types